JCR Pharmaceuticals Co., Ltd.
JCRRF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $7 | $9 |
| % Growth | 45.4% | -99.2% | -22% | – |
| Cost of Goods Sold | $0 | $0 | $4 | $3 |
| Gross Profit | $0 | $0 | $3 | $7 |
| % Margin | 84.3% | 72.1% | 39.8% | 71% |
| R&D Expenses | $0 | $0 | $15 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $7 | $7 | $7 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$7 | -$13 | $0 |
| Operating Expenses | $0 | $0 | $9 | $7 |
| Operating Income | $0 | -$0 | -$6 | -$0 |
| % Margin | 23% | -7.5% | -82% | -0.2% |
| Other Income/Exp. Net | $0 | -$0 | -$0 | $0 |
| Pre-Tax Income | $0 | -$0 | -$6 | $0 |
| Tax Expense | $0 | -$0 | $2 | $0 |
| Net Income | $0 | -$1 | -$4 | $0 |
| % Margin | 17.6% | -918.3% | -58.2% | 1.2% |
| EPS | 0.13 | -4.48 | -34.28 | 0.93 |
| % Growth | 102.9% | 86.9% | -3,786% | – |
| EPS Diluted | 0.13 | -4.48 | -34.28 | 0.93 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $1 | $1 | $1 |
| EBITDA | $0 | $0 | -$5 | $1 |
| % Margin | 32% | 335.5% | -70.9% | 8% |